# United States Patent 10,010,517: Claim Scope, Vascepa Patent Landscape, Exclusivity and Generic Risk

U.S. Patent No. 10,010,517 protects a clinical-use method for administering high-purity ethyl-EPA, commercially icosapent ethyl and marketed as Vascepa, to statin-treated patients with triglycerides from about 200 mg/dL to less than 500 mg/dL. The independent claim requires five principal elements: statin therapy, the specified triglyceride range, at least 96% pure ethyl-EPA, a daily dose of 2,000 to about 5,000 mg, and treatment for at least about four weeks.

The patent is narrower than a general composition patent but commercially important because it tracks the therapeutic population and dosing regimen associated with Vascepa’s cardiovascular-risk-reduction and triglyceride-lowering franchise. Its practical enforceability depends on the generic product label, the marketing theory, physician prescribing, and proof of induced infringement. The patent’s earliest priority date is in 2011, giving it a patent-term endpoint in the 2030s rather than the 2029 endpoint associated with several earlier Vascepa patents.

What does U.S. Patent 10,010,517 cover?

The patent covers a method of lowering triglycerides with high-purity ethyl-EPA in a patient who is already receiving statin therapy.

Claim element	Requirement in claim 1	Commercial significance
Patient population	Triglycerides of about 200 mg/dL to less than 500 mg/dL	Targets moderate hypertriglyceridemia rather than severe hypertriglyceridemia
Background therapy	Stable statin therapy	Links the claim to a statin-treated cardiovascular-risk population
Active ingredient	Pharmaceutical composition containing at least 96% pure ethyl-EPA	Reads on high-purity icosapent ethyl products
Daily dose	2,000 mg to about 5,000 mg	Encompasses the approved 2-g/day and 4-g/day regimens
Treatment duration	At least about four weeks	Establishes a minimum treatment period
Result	Lower fasting triglycerides compared with stable statin therapy without concomitant ethyl-EPA	Creates a treatment-outcome limitation

The claim is a method claim, not a claim to ethyl-EPA as a chemical compound. It does not broadly prevent manufacture or sale of every EPA product. It targets administration of a qualifying product to a qualifying patient population.

How do claims 1 through 12 differ?

Claim 1 is the controlling independent claim. Claims 2 through 12 add laboratory outcomes, composition limits, duration, or dosage-unit restrictions.

Claims 2 and 3: non-HDL-C reduction

Claims 2 and 3 require reduction in non-HDL cholesterol of at least about 3% or at least about 5%, respectively. These claims are narrower than claim 1 because they impose a measurable lipid outcome.

The claims do not use a single mandatory comparator. Claims 4 and 5 specify reduction relative to placebo control. Claims 6 and 7 specify reduction relative to the subject’s baseline non-HDL-C level. This creates two distinct measurement frameworks:

Comparison with placebo.
Comparison with the treated patient’s baseline.

A generic product could satisfy the active-treatment, dose, purity, and patient-population elements while disputing whether the claimed non-HDL-C reduction is present in an individual patient or across the relevant clinical population.

Claim 8: HDL-C increase

Claim 8 requires an increase in HDL-C. It does not specify a minimum percentage increase. That makes the limitation technically broad but potentially difficult to prove consistently because the claim requires an increase, not merely a statistically favorable trend in a clinical study.

Claim 9: total-cholesterol reduction

Claim 9 requires a reduction in total cholesterol. Like claim 8, it does not specify a numerical threshold.

Claim 10: DHA limitation

Claim 10 requires less than about 20% docosahexaenoic acid, measured by weight of total fatty acids. This limitation separates the claimed product from mixed EPA/DHA omega-3 formulations.

It is particularly relevant to generic substitution analysis. A generic icosapent ethyl product with a composition materially equivalent to Vascepa is likely to satisfy the EPA-purity and DHA limitations. A conventional fish-oil product containing substantial DHA may not.

Claim 11: 12-week duration

Claim 11 requires treatment for at least about 12 weeks. It is narrower than claim 1’s four-week minimum and corresponds more closely to the duration of many lipid-efficacy studies.

Claim 12: dosage units

Claim 12 requires administration in one or more dosage units per day. The claim does not require a specific capsule strength, but it is compatible with the 1-gram capsules used for Vascepa. A 4-gram daily regimen can be administered as four 1-gram capsules or through another dosage-unit configuration.

What is the patent’s priority date and expiration timing?

U.S. Patent 10,010,517 was granted on June 26, 2018. The patent belongs to the Amarin ethyl-EPA method-of-use family and claims priority to an August 2011 filing date. The ordinary patent-term calculation points to an August 2032 expiration date, subject to patent-term adjustment and any applicable statutory extension.

Event	Date or period
Earliest relevant priority	August 2011
U.S. patent application family	2010s continuation practice
Grant of U.S. 10,010,517	June 26, 2018
Expected ordinary expiration	August 2032, subject to adjustment
FDA approval of Vascepa	December 2012
First U.S. generic launches	2020

The exact Orange Book expiration field and any patent-term adjustment should be verified against the current FDA Orange Book and USPTO patent record. The key commercial point is that this patent has a later expiry profile than the earliest Vascepa patents, many of which trace to earlier priority dates and expire around 2029.

What FDA indication does the patent track?

Vascepa is approved for two principal uses:

As an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia, generally triglycerides of at least 500 mg/dL.
As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adults with elevated triglycerides and established cardiovascular disease or diabetes plus additional cardiovascular risk factors.

The patent’s claim 1 range, about 200 mg/dL to less than 500 mg/dL, aligns more closely with the cardiovascular-risk-reduction population than with the original severe-hypertriglyceridemia approval. The FDA expanded Vascepa’s label in December 2019 after the REDUCE-IT cardiovascular-outcomes study. The label identifies 4 grams per day as the recommended dosage for the cardiovascular-risk-reduction indication and for severe hypertriglyceridemia. [1]

The patent is therefore strategically connected to the post-2019, statin-background indication rather than only to triglyceride lowering in patients with very high triglycerides.

What is the Orange Book status of U.S. Patent 10,010,517?

The patent is part of the Vascepa patent estate and has been identified in connection with the branded product’s FDA exclusivity and generic litigation. Orange Book listing status can change through delisting, corrections, product-specific listing changes, or patent-term updates.

The listed patent categories relevant to Vascepa have included:

Composition and formulation patents.
Method-of-use patents covering triglyceride lowering.
Method-of-use patents covering cardiovascular-risk reduction.
Patents directed to high-purity EPA formulations and dosing.

A patent listed in the Orange Book does not automatically establish infringement. It requires a product-specific analysis under the Hatch-Waxman framework. A generic applicant may file a Paragraph IV certification challenging validity, enforceability, or infringement, or a Paragraph III certification accepting delayed entry.

How strong is the patent estate for Vascepa and icosapent ethyl?

The Vascepa estate is layered rather than dependent on a single patent. Its strength comes from overlapping claim categories.

Patent category	Typical protected subject matter	Principal risk to generic applicants
Composition	High-purity ethyl-EPA and low-DHA compositions	Product may fall within the claimed chemical profile
Formulation	Capsules, excipients, stability and delivery characteristics	Product-by-process and formulation overlap
Triglyceride methods	Administration to patients with elevated triglycerides	Label and prescribing evidence
Cardiovascular methods	Statin-treated patients at elevated cardiovascular risk	Skinny-label and induced-infringement exposure
Dose and duration	2 g/day or 4 g/day, treatment over specified periods	Label language and actual use
Manufacturing	Purification and preparation of ethyl-EPA	Process overlap and trade-secret alternatives

U.S. Patent 10,010,517 is strongest when a competing product has all of the following characteristics:

icosapent ethyl or equivalent high-purity ethyl-EPA;
a label covering statin-treated adults;
triglycerides within the claimed range;
a 2-gram or 4-gram daily dose;
language encouraging treatment for at least four weeks; and
clinical or promotional materials referring to non-HDL-C, HDL-C, or total-cholesterol effects.

The patent is weaker against a product marketed solely for severe hypertriglyceridemia at levels of 500 mg/dL or higher, provided the generic label and commercial conduct do not encourage use in the claimed 200-to-less-than-500 mg/dL population.

Which companies challenged Vascepa patents?

The principal generic challengers included Hikma Pharmaceuticals, Dr. Reddy’s Laboratories, Teva Pharmaceuticals, Apotex, and related abbreviated new drug application sponsors. Multiple defendants challenged different subsets of the Vascepa patents through Paragraph IV certifications and subsequent federal litigation.

The most commercially significant case was Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc. and related defendants in the U.S. District Court for the District of Delaware. The litigation concerned patents covering Vascepa’s approved indications, including patents associated with cardiovascular-risk reduction and triglyceride lowering. [2]

Generic entry occurred in 2020 after litigation outcomes and settlement arrangements allowed abbreviated new drug application products to enter the market. The entry materially changed Vascepa’s competitive position even though later-expiring patents remained part of the patent landscape.

What Paragraph IV and skinny-label risks apply?

A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. For a method-of-use patent such as 10,010,517, the central issue is usually whether the proposed label and foreseeable use induce infringement.

A generic sponsor may seek to limit risk through a section viii statement, commonly called a skinny label, carving out a patented indication or method of use. That strategy is relevant to claim 1 because the claim is tied to statin-treated patients with triglycerides below 500 mg/dL.

The risk analysis has several layers:

Label text

If the generic label expressly includes the statin-treated, moderate-hypertriglyceridemia population, it is more likely to support an induced-infringement claim.

Prescribing instructions

A label that recommends 4 grams per day in patients whose triglycerides are 200 mg/dL to less than 500 mg/dL creates greater exposure than a label limited to triglycerides of at least 500 mg/dL.

Promotional conduct

Sales materials, medical-information responses, reimbursement materials, and comparative claims can undermine a carve-out if they encourage use for the patented indication.

Physician and patient use

Actual infringement by physicians or patients is not enough by itself to establish generic liability. The branded plaintiff generally must connect the generic sponsor’s label or conduct to induced infringement.

Clinical-outcome limitations

Claims 2 through 9 add lipid outcomes. Those limitations can complicate proof because the plaintiff may need evidence concerning the claimed reduction or increase, the measurement period, and the specified comparator.

What patent litigation affects U.S. Patent 10,010,517?

The patent sits within the broader Amarin-Vascepa litigation record rather than operating as an isolated asset. Courts evaluating the Vascepa estate have addressed:

obviousness based on prior omega-3 and EPA literature;
written-description and enablement issues;
anticipation;
induced infringement based on generic labels;
the effect of indication carve-outs;
patent-listing and Hatch-Waxman procedure.

The Federal Circuit’s Vascepa-related decisions have limited the ability of a brand owner to rely solely on the fact that a generic product will foreseeably be used for a patented indication. The label and affirmative conduct remain central. [3]

The commercial result is a split landscape: generic products can enter for non-patented uses, while the brand owner may continue asserting later-expiring method-of-use patents against conduct that promotes or encourages the patented population.

What settlements and licensing arrangements affected generic entry?

Generic entry followed litigation settlements and other arrangements involving Amarin and generic sponsors. The settlements controlled timing, indication carve-outs, and the scope of permitted commercialization. Publicly reported settlement terms varied by defendant and patent.

These agreements mattered because a generic sponsor could obtain market access before every asserted patent expired if the parties resolved litigation through an agreed launch date, label limitation, or other commercial arrangement. The existence of a settlement does not establish that U.S. Patent 10,010,517 was valid or infringed. It establishes that the parties allocated litigation and launch risk contractually.

No broad license to the entire ethyl-EPA patent estate should be inferred from an individual generic settlement. Rights are generally product-, indication-, patent-, and defendant-specific.

How does U.S. Patent 10,010,517 compare with other Vascepa patents?

Issue	U.S. 10,010,517	Earlier Vascepa patents	Later Vascepa patents
Primary focus	Statin-treated patients with moderate triglycerides	Composition, formulation, triglyceride lowering	Cardiovascular outcomes, dosing, later method claims
Claim type	Method of treatment	Mixed composition and method claims	Predominantly method and use claims
Key dose	2,000 to about 5,000 mg/day	Varies	Often 4 g/day or indication-specific
Patient range	About 200 to less than 500 mg/dL	Varies	Often cardiovascular-risk populations
Expected expiry profile	Around August 2032, subject to adjustment	Several patents around 2029	Some family members into the early 2030s
Generic vulnerability	Label and induced infringement	Product overlap and validity	Label, indication, and clinical-use proof

The patent’s later expiry provides residual protection after some early formulation and composition patents expire. Its limitation is that the claims are tied to a defined patient population and treatment context.

What generic launch scenarios exist for icosapent ethyl?

Scenario 1: Immediate broad-label launch

A generic sponsor launches with a label covering both severe hypertriglyceridemia and cardiovascular-risk reduction. This creates the highest exposure under claim 1 and related method-of-use claims.

Scenario 2: Skinny-label launch

The sponsor removes or omits the moderate-triglyceride, statin-treated cardiovascular indication. This reduces direct label-based infringement risk but does not eliminate exposure from promotional conduct or later label changes.

Scenario 3: Severe-hypertriglyceridemia-only launch

A label limited to triglycerides of at least 500 mg/dL is less aligned with claim 1’s range. The sponsor still faces composition, formulation, and other method patents.

Scenario 4: At-risk launch after Paragraph IV litigation

The generic enters before final resolution of every patent issue. It faces damages, injunction, and potential launch disruption if the brand later prevails.

What geographic coverage does the patent provide?

U.S. Patent 10,010,517 provides rights only in the United States. It can support an action against U.S. manufacture, importation, sale, offer for sale, or use within the scope of 35 U.S.C. § 271.

It does not directly control:

Canadian or European sales;
manufacturing conducted entirely outside the United States, subject to U.S. importation rules;
foreign method-of-use claims;
foreign regulatory labels.

The broader Amarin estate includes foreign counterparts, but foreign validity, claim scope, term, listing practices, and enforcement differ by jurisdiction.

What manufacturing and intellectual-property barriers remain?

The patent does not create a complete manufacturing monopoly over all EPA products. A competitor may attempt to design around it by:

using an EPA formulation below the claimed purity threshold;
using a materially different fatty-acid profile;
targeting a non-overlapping patient population;
limiting the label to non-patented uses;
changing the dose or dosing instructions;
developing a different delivery system.

These approaches have commercial and regulatory costs. A product that falls outside the method claim may still need to demonstrate pharmaceutical equivalence, bioequivalence, stability, impurity control, and manufacturing consistency under the FDA ANDA pathway.

For icosapent ethyl, the practical manufacturing barrier is not only patent scope. It includes purification of EPA ethyl ester, control of oxidation products, capsule stability, raw-material sourcing, and reproducibility of the high-purity fatty-acid profile.

Key Takeaways

U.S. Patent 10,010,517 is a method-of-use patent for high-purity ethyl-EPA in statin-treated patients with triglycerides of about 200 mg/dL to less than 500 mg/dL.
Claim 1 covers 2,000 to about 5,000 mg per day for at least four weeks and requires lower fasting triglycerides than stable statin therapy without ethyl-EPA.
Claims 2 through 9 add non-HDL-C, HDL-C, and total-cholesterol outcomes. Claims 4 through 7 define placebo and baseline comparators.
Claim 10 requires less than about 20% DHA by weight of total fatty acids, strengthening the distinction from mixed EPA/DHA products.
The patent traces to an August 2011 priority date and is expected to expire around August 2032, subject to patent-term adjustment.
Generic risk is concentrated in label design, statin-treated moderate-hypertriglyceridemia use, promotional conduct, and induced-infringement evidence.
Generic icosapent ethyl products entered the U.S. market in 2020 after Vascepa litigation and settlement activity.
The patent is one layer of a broader Vascepa estate that includes composition, formulation, manufacturing, and additional method-of-use patents.

FAQs About U.S. Patent 10,010,517

Does U.S. Patent 10,010,517 cover Vascepa itself?

No. It covers specified methods of administering high-purity ethyl-EPA. It is not a broad chemical-composition claim to every form of EPA or every icosapent ethyl product.

Can a generic icosapent ethyl product avoid this patent with a skinny label?

Potentially, if the label omits the claimed statin-treated moderate-triglyceridemia use and the sponsor avoids conduct that encourages that use. The strategy does not eliminate exposure under other Vascepa patents.

Does the patent require a 4-gram daily dose?

No. Claim 1 covers 2,000 mg to about 5,000 mg per day. The approved 4-gram daily regimen falls within that range, but the claim also encompasses a 2-gram daily dose.

Does a triglyceride level of exactly 500 mg/dL fall within claim 1?

The claim specifies less than 500 mg/dL. A level exactly at 500 mg/dL is outside that literal numerical range, although the treatment record and claim construction could affect a particular infringement analysis.

Is U.S. Patent 10,010,517 relevant to biosimilar competition?

No. Icosapent ethyl is a small-molecule drug, not a biologic. The relevant competitors are ANDA-based generic products, not biosimilars under the Public Health Service Act.

References

U.S. Food and Drug Administration. (2024). Vascepa (icosapent ethyl) prescribing information.
Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., No. 1:20-cv-01630, U.S. District Court for the District of Delaware.
U.S. Court of Appeals for the Federal Circuit. (2023). Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., Vascepa-related appellate decisions.
U.S. Patent and Trademark Office. (2018). U.S. Patent No. 10,010,517, Methods of lowering triglycerides in a subject.
U.S. Food and Drug Administration. (2024). Approved Drug Products with Therapeutic Equivalence Evaluations, Orange Book.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-001	Jul 26, 2012	AB	RX	Yes	Yes	10,010,517	⤷ Start Trial				USE OF VASCEPA TO LOWER TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY	⤷ Start Trial
Amarin Pharms	VASCEPA	icosapent ethyl	CAPSULE;ORAL	202057-002	Feb 16, 2017	AB	RX	Yes	No	10,010,517	⤷ Start Trial				USE OF VASCEPA TO LOWER TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG/DL TO LESS THAN ABOUT 500 MG/DL) AND ON STATIN THERAPY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010241571	⤷ Start Trial
Brazil	PI1011876	⤷ Start Trial
Canada	2759284	⤷ Start Trial
China	102458109	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 10,010,517